Last edition
News about
Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer
Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.
Innovent and Lilly Partner to Commercialise Verzenios in China
Innovent Biologics and Eli Lilly have signed a commercialisation agreement for Verzenios (abemaciclib) in mainland China, expanding access to the CDK4/6 inhibitor for cancer patients.
Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD
Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.
AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma
AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Akums Launches DCGI-Approved Triple-Action Therapy for Diabetic Neuropathic Pain
Akums Drugs & Pharmaceuticals has introduced a DCGI-approved triple-action capsule that combines pregabalin, methylcobalamin and delayed-release duloxetine to offer comprehensive management of diabetic peripheral neuropathic pain while supporting nerve regeneration.
Artivion Secures US FDA Approval for AMDS Hybrid Prosthesis to Treat Acute Aortic Dissections
Artivion has received US FDA approval for its AMDS Hybrid Prosthesis, enabling broader adoption of the aortic arch remodelling device that has demonstrated significant reductions in mortality and major complications for patients with acute DeBakey Type I aortic dissections.
Jagsonpal Pharmaceuticals to Acquire 85 Percent Stake in Aequitas Healthcare for INR 20.8 Crore
Aeguitas Healthcare’s acquisition marks Jagsonpal's entry into the hospital pharmaceutical segment, strengthening its omnichannel healthcare strategy and expanding its institutional market presence.
Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan
Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.
Cadila Pharmaceuticals and Singapore-based Wellesta Holdings have signed an MoU to establish a joint venture focused on expanding access to high-quality healthcare solutions across Southeast Asia and other emerging markets.
Roche's Enspryng Receives FDA Priority Review for Thyroid Eye Disease
Roche's Enspryng has received FDA Priority Review for thyroid eye disease after Phase 3 studies demonstrated clinically meaningful improvements in eye bulging, disease activity and double vision, with a regulatory decision expected by October 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy